Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study

von Wyl, Viktor; Klimkait, Thomas; Yerly, Sabine; Nicca, Dunja; Furrer, Hansjakob; Cavassini, Matthias; Calmy, Alexandra; Bernasconi, Enos; Böni, Jürg; Aubert, Vincent; Günthard, Huldrych F.; Bucher, Heiner C.; Glass, Tracy R.
October 2013
PLoS ONE;Oct2013, Vol. 8 Issue 10, p1
Academic Journal
Background:Non-adherence is one of the strongest predictors of therapeutic failure in HIV-positive patients. Virologic failure with subsequent emergence of resistance reduces future treatment options and long-term clinical success. Methods:Prospective observational cohort study including patients starting new class of antiretroviral therapy (ART) between 2003 and 2010. Participants were naïve to ART class and completed ≥1 adherence questionnaire prior to resistance testing. Outcomes were development of any IAS-USA, class-specific, or M184V mutations. Associations between adherence and resistance were estimated using logistic regression models stratified by ART class. Results:Of 314 included individuals, 162 started NNRTI and 152 a PI/r regimen. Adherence was similar between groups with 85% reporting adherence ≥95%. Number of new mutations increased with increasing non-adherence. In NNRTI group, multivariable models indicated a significant linear association in odds of developing IAS-USA (odds ratio (OR) 1.66, 95% confidence interval (CI): 1.04-2.67) or class-specific (OR 1.65, 95% CI: 1.00-2.70) mutations. Levels of drug resistance were considerably lower in PI/r group and adherence was only significantly associated with M184V mutations (OR 8.38, 95% CI: 1.26-55.70). Adherence was significantly associated with HIV RNA in PI/r but not NNRTI regimens. Conclusion:Therapies containing PI/r appear more forgiving to incomplete adherence compared with NNRTI regimens, which allow higher levels of resistance, even with adherence above 95%. However, in failing PI/r regimens good adherence may prevent accumulation of further resistance mutations and therefore help to preserve future drug options. In contrast, adherence levels have little impact on NNRTI treatments once the first mutations have emerged.


Related Articles

  • Evaluating the Role of Etravirine in the Second-Line Antiretroviral Therapy After Failing an Initial Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimen in a Resource-Limited Setting. Sungkanuparph, Somnuek; Manosuthi, Weerawat; Kiertiburanakul, Sasisopin; Piyavong, Bucha; Chantratita, Wasun // Current HIV Research;Sep2008, Vol. 6 Issue 5, p474 

    Etravirine demonstrates activity against NNRTI-resistant HIV-1 but its efficacy depends on the number of etravirine resistance-associated mutations (RAMs). This study aimed to evaluate the role of etravirine in the second regimen in a resource-limited setting. Genotype resistance assay was...

  • Prevalence of Genotypic Resistance in Untreated HIV Patients in Spain. Eiros, J. M.; Labayru, C.; Hernández, B.; Ortega, M.; Bachiller, P.; de Lejarazu, R. Ortiz // European Journal of Clinical Microbiology & Infectious Diseases;Apr2002, Vol. 21 Issue 4, p310 

    The aims of this retrospective study were to assess the prevalence of primary genotypic resistance to antiretroviral drugs in untreated HIV patients in Spain using the line probe assay and to determine its possible relationship to several epidemiological variables. The global prevalence of...

  • Pre-Screening HIV-1 Reverse Transcriptase Resistance Mutations in Subtype B Patients Using a Novel Multiplex Primer Extension Assay. Jakobsen, Martin Roelsgaard; Aggerholm, Anni; J�rgensen, Louise Bruun; Laursen, Alex; �stergaard, Lars // Current HIV Research;Jul2009, Vol. 7 Issue 4, p398 

    Antiretroviral therapy is standard treatment for HIV-infected patients. Such therapy has decreased mortality and morbidity, but treatment success is often jeopardized by the emergence of viral drug resistance. Moreover, in recent years there has been a reported rise in the incidence of...

  • Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. Saracino, Annalisa; Monno, Laura; Tartaglia, Alessandra; Tinelli, Carmine; Seminari, Elena; Maggiolo, Franco; Bonora, Stefano; Rusconi, Stefano; Micheli, Valeria; Caputo, Sergio Lo; Lazzaroni, Laura; Ferrara, Sergio; Ladisa, Nicoletta; Nasta, Paola; Parruti, Giustino; Bellagamba, Rita; Forbici, Federica; Angarano, Gioacchino // Current HIV Research;Jul2009, Vol. 7 Issue 4, p425 

    Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resistant strains, can be used in salvage therapies for multi-experienced HIV patients due to its peculiar resistance profile including 21 mutations at 16 protease positions according to International...

  • Long-term maraviroc use as salvage therapy in HIV-2 infection. Caixas, Umbelina; Ferreira, Joana; Marinho, Aline T.; Faustino, Inês; Grilo, Nádia M.; Lampreia, Fátima; Germano, Isabel; Monteiro, Emília C.; Pereira, Sofia A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2012, Vol. 67 Issue 10, p2538 

    The article discusses the case of a patient diagnosed with human immunodeficiency virus (HIV)-2. Information on the patient's combined antiretroviral therapy (cART) is provided. Atazanavir/ritonavir served as substitutes to lopinavir/ritonavir due to the patient's intolerance and poor adherence...

  • Characterization of HIV-1 Genotypes and Antiretroviral Drug-resistance Mutations among Patients in Burkina Faso. Kagone, T. S.; Hien, H.; Meda, N.; Diagbouga, P. S.; Sawadogo, A.; Drabo, J.; Peeters, M.; Vergne, L.; Delaporte, E.; De Souza, C.; Gbeassor, M.; Simpore, J. // Pakistan Journal of Biological Sciences;2011, Vol. 14 Issue 6, p392 

    No abstract available.

  • Resistencia a fármacos en pacientes en tratamiento antirretroviral, Cali, Colombia, 2008-2010. Martínez-Cajas, Jorge L.; Mueses-Marín, Héctor F.; Galindo-Orrego, Pablo; Agudelo, Juan F.; Galindo-Quintero, Jaime // Biomédica: Revista del Instituto Nacional de Salud;oct2013, Vol. 33 Issue 4, p631 

    Introduction: Little has been published in Colombia on HIV drug resistance in patients taking antiretroviral treatment (ART). Currently, the Colombian guidelines do not recommend the use of genotypic antiretroviral resistance tests (GART) for treatment-naive patients or for those experiencing a...

  • Genotypic resistance testing in HIV by arrayed primer extension. Schanné, Michaela; Bodem, Jochen; Gerhold-Ay, Aslihan; Jacob, Anette; Fellenberg, Kurt; Kräusslich, Hans-Georg; Hoheisel, Jörg D. // Analytical & Bioanalytical Chemistry;Jul2008, Vol. 391 Issue 5, p1661 

    The analysis of mutations that are associated with the occurrence of drug resistance is important for monitoring the antiretroviral therapy of patients infected with human immunodeficiency virus (HIV). Here, we describe the establishment and successful application of Arrayed Primer Extension...

  • Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing. Bansode, Vijay; McCormack, Grace P.; Crampin, Amelia C.; Ngwira, Bagrey; Shrestha, Ram K.; French, Neil; Glynn, Judith R.; Travers, Simon A. // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: The role of HIV-1 RNA in the emergence of resistance to antiretroviral therapies (ARTs) is well documented while less is known about the role of historical viruses stored in the proviral DNA. The primary focus of this work was to characterize the genetic diversity and evolution of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics